News

NuThrax is a combination of BioThrax (Anthrax Vaccine Adsorbed) and the immunostimulatory oligodeoxynucleotide compound CPG 7909. The contract includes a 30-month base period of performance to develop NuThrax

In the trial, NGM282 showed statistically significant, dose-dependent and clinically meaningful reductions in alkaline phosphatase (ALP), a primary indicator of disease activity, as well as substantial reductions in

The probiotic strains used in HLC Baby B and HLC Baby F probiotic formulas were evaluated in a recent clinical trial, in which they were found to be

The new laboratory space, located within the Human BioMolecular Research Institute, provides Regen with access to molecular and cellular biology facilities critical to its cancer stem cell research.

Canada-based Portage Biotech holds 54% equity of Biohaven, a privately-held biopharmaceutical firm engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system. Catalent’s

A total of 834 patients were included in the trial and were given Keytruda 10mg/kg every three weeks, Keytruda 10mg/kg every two weeks, or four cycles of ipilimumab

According to the company, the combination was generally well tolerated and all patients completed 12 weeks of treatment. The trial evaluated two doses of VX-661 100mg once daily

As part of the deal, Can-Fite will receive an upfront payment of C$1.65m and is eligible for milestone payments of up to C$2m and royalties from product sales

The new cancer therapeutics will be developed using both GenVec’s gene delivery platform and TheraBiologics’ neural stem cell (NSC) technology. Under the deal, GenVec will contribute technology, know-how,